PAPP‐A is also overexpressed in a subset of human ovarian tumors, and weekly treatment of mice harboring these intraperitoneal patient tumorgrafts with the inhibitory antibody, mAb‐PA, could reduce tumor size and ascites burden. This evidence concerns the gene PAPPA and neoplasm.